NCT04158804View on ClinicalTrials.gov

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

NACompletedINTERVENTIONAL

Enrollment

700

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

June 17, 2023

Study Completion Date

June 17, 2023

Conditions

Pneumonia, Bacterial

Interventions

DIAGNOSTIC_TEST

procalcitonin

accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection

Trial Locations (6)

30303

Grady Memorial Hospital, Atlanta

76104

Texas Health Harris Methodist Hospital, Fort Worth

06790

Charlotte Hungerford Hospital, Torrington

02114

Massachusetts General Hospital, Boston

02557

Martha's Vineyard Hospital, Oak Bluffs

01970

North Shore Medical Center, Salem

All Listed Sponsors

collaborator

BRAHMS GmbH

UNKNOWN

collaborator

Thermo Fisher Scientific, Inc

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04158804 - PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT | Biotech Hunter | Biotech Hunter